Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SCN4A | P35499 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10031780 | 1.00 | ADORA3 (0.55) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL22305236 | 1.00 | ADORA3 (0.55) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7387546 | 1.00 | ADORA3 (0.55) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7600467 | 1.00 | ADORA3 (0.55) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7810245 | 1.00 | ADORA3 (0.55) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL5838534 | 0.95 | ABCC3 (0.55) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL4956494 | 0.89 | CYP3A4 (0.57) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL5373760 | 0.89 | ABCC3 (0.47) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL13536317 | 0.88 | ABCC3 (0.58) | ADORA3ABCC3ABCC4ABCB11PGR | |
| SCHEMBL30261823 | 0.88 | ABCC3 (0.65) | ADORA3ABCC3ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1170289-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2002-01-09 | — | — | EP | claimed |
| CN-110903249-B | Lopinavir prepared by one-pot method | 厦门蔚嘉制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-111018791-B | Novel method for preparing lopinavir | 厦门蔚嘉制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-111018791-A | Novel method for preparing lopinavir | 厦门蔚嘉制药有限公司 | 2020-04-17 | — | — | CN | disclosed |
| CN-110903249-A | Lopinavir prepared by one-pot method | 厦门蔚嘉制药有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20140303369-A1 | Crystalline Pharmaceutical | ABBVIE INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8796451-B2 | Crystalline pharmaceutical | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2393786-B1 | NOVEL POLYMORPHS OF LOPINAVIR | HETERO RESEARCH FOUNDATION (IN) | 2014-01-22 | — | — | EP | disclosed |
| US-8445506-B2 | Polymorphs of lopinavir | HETERO RESEARCH FOUNDATION (IN) | 2013-05-21 | — | — | US | disclosed |
| US-20120108529-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2010089753-A2 | NOVEL POLYMORPHS OF LOPINAVIR | HETERO RESEARCH FOUNDATION (IN) | 2010-08-12 | — | — | WO | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070027172-A1 | Crystalline pharmaceutical | ABBOTT LABORATORIES | 2007-02-01 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2006100552-A1 | PROCESSES FOR THE PREPARATION OF LOPINAVIR AND ITS INTERMEDIATE - (S)-TETRAHYDRO-ALPHA-(1-METHYLETHYL)-2-OXO-1(2H)-PYRIMIDINEACETIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100552-A1 | PROCESSES FOR THE PREPARATION OF LOPINAVIR AND ITS INTERMEDIATE - (S)-TETRAHYDRO-ALPHA-(1-METHYLETHYL)-2-OXO-1(2H)-PYRIMIDINEACETIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006090264-A1 | A PROCESS FOR THE SYNTHESIS OF 2-AMINO-5-PROTECTED AMINO-3-HYDROXY-1, 6-DIPHENYLHEXANE OR A SALT THEREOF - AN INTERMEDIATE FOR ANTIVIRAL DRUGS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | WO | disclosed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303369-A1 | Crystalline Pharmaceutical | PYGL, ACE, HDLBP | ADORA3 2140/4885ABCC3 113/4885ABCC4 133/4885 |
| US-20120108529-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | ADORA3 4697/4885ABCC3 4439/4885ABCC4 4714/4885 |
| US-20070027172-A1 | Crystalline pharmaceutical | PYGL, ACE, HDLBP | ADORA3 2140/4885ABCC3 112/4885ABCC4 133/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ADORA3 3601/4885ABCC3 2688/4885ABCC4 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.